• 1
    Noon L. Prophylactic inoculation against hay fever. Lancet 1911;1:15721573.
  • 2
    Prausnitz C, Kuestner H. Studien über die Überempfindlichkeit. Zentralbl Bakteriol 1921;86:160169.
  • 3
    Cooke RA, Barnard JH, Hebald S, Stull A. Serological evidence of immunity with coexisting sensitization in a type of human allergy. J Exp Med 1935;62:733750.
  • 4
    Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 1998;102:558562.
  • 5
    Larché M, Akdis CA, Valenta R. Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol 2006;6:761771.
  • 6
    Möller C, Dreborg S, Ferdousi HA, Halken S, Høst A, Jacobsen L et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002;109:251256.
  • 7
    Durham SR, Walker SM, Varga EM, Jacobson MR, O’Brien F, Noble W et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999;341:468475.
  • 8
    Valenta R, Ferreira F, Focke-Tejkl M, Linhart B, Niederberger V, Swoboda I et al. From allergen genes to allergy vaccines. Annu Rev Immunol 2010;28:211241.
  • 9
    Focke M, Marth K, Flicker S, Valenta R. Heterogeneity of commercial timothy grass pollen extracts. Clin Exp Allergy 2008;38:14001408.
  • 10
    Focke M, Marth K, Valenta R. Molecular composition and biological activity of commercial birch pollen allergen extracts. Eur J Clin Invest 2009;39:429436.
  • 11
    Curin M, Reininger R, Swoboda I, Focke M, Valenta R, Spitzauer S. Skin prick test extracts for dog allergy diagnosis show considerable variations regarding the content of major and minor dog allergens. Int Arch Allergy Immunol 2010;154:258263.
  • 12
    Brunetto B, Tinghino R, Braschi MC, Antonicelli L, Pini C, Iacovacci P. Characterization and comparison of commercially available mite extracts for in vivo diagnosis. Allergy 2010;65:184190.
  • 13
    Fang KS, Vitale M, Fehlner P, King TP. cDNA cloning and primary structure of a white-face hornet venom allergen, antigen 5. Proc Natl Acad Sci USA 1988;85:895899.
  • 14
    Chua KY, Stewart GA, Thomas WR, Simpson RJ, Dilworth RJ, Plozza TM et al. Sequence analysis of cDNA coding for a major house dust mite allergen, Der p 1. Homology with cysteine proteases. J Exp Med 1988;167:175182.
  • 15
    Breiteneder H, Pettenburger K, Bito A, Valenta R, Kraft D, Rumpold H et al. The gene coding for the major birch pollen allergen Betv1, is highly homologous to a pea disease resistance response gene. EMBO J 1989;8:19351938.
  • 16
    Sehon AH, Kraft D, Kunkel G. Epitopes of Atopic Allergens. Brussels: UCB Inst, Allergy, 1990.
  • 17
    Valenta R, Breiteneder H, Petternburger K, Breitenbach M, Rumpold H, Kraft D et al. Homology of the major birch-pollen allergen, Bet v I, with the major pollen allergens of alder, hazel, and hornbeam at the nucleic acid level as determined by cross-hybridization. J Allergy Clin Immunol 1991;87:677682.
  • 18
    Ebner C, Birkner T, Valenta R, Rumpold H, Breitenbach M, Scheiner O et al. Common epitopes of birch pollen and apples--studies by western and northern blot. J Allergy Clin Immunol 1991;88:588594.
  • 19
    Ipsen H, Løwenstein DH. Immunochemical characterization of the major allergen from birch pollen (Betula verrucosa) and its relation to alder and hazel. J Allergy Clin Immunol 1982;69:127.
  • 20
    Nüchel Petersen B, Janniche H, Munch EP, Wihl JA, Böwadt H, Ipsen H et al. Immunotherapy with partially purified and standardized tree pollen extracts. I. Clinical results from a three-year double-blind study of patients treated with pollen extracts either of birch or combinations of alder, birch and hazel. Allergy 1988;43:353362.
  • 21
    Wihl JA, Ipsen H, Petersen BN, Munch EP, Janniche H, Løwenstein H. Immunotherapy with partially purified and standardized tree pollen extracts. II. Results of skin prick tests and nasal provocation tests from a three-year double-blind study of patients treated with pollen extracts either of birch or combinations of alder, birch and hazel. Allergy 1988;43:363369.
  • 22
    Ipsen H, Schwartz B, Wihl JA, Petersen BN, Munch EP, Janniche H et al. Immunotherapy with partially purified and standardized tree pollen extracts. III. Specific IgE response to the major allergens of alder, birch and hazel pollen during immunotherapy. Allergy 1988;43:370377.
  • 23
    Valenta R, Duchene M, Pettenburger K, Sillaber C, Valent P, Bettelheim P et al. Identification of profilin as a novel pollen allergen; IgE autoreactivity in sensitized individuals. Science 1991;253:557560.
  • 24
    Valenta R, Duchene M, Ebner C, Valent P, Sillaber C, Deviller P et al. Profilins constitute a novel family of functional plant pan-allergens. J Exp Med 1992;175:377385.
  • 25
    Valenta R, Steinberger P, Duchêne M, Kraft D. Immunological and structural similarities among allergens: prerequisite for a specific and component-based therapy of allergy. Immunol Cell Biol 1996;74:187194.
  • 26
    Valenta R, Duchene M, Vrtala S, Birkner T, Ebner C, Hirschwehr R et al. Recombinant allergens for immunoblot diagnosis of tree-pollen allergy. J Allergy Clin Immunol 1991;88:889894.
  • 27
    Valenta R, Vrtala S, Ebner C, Kraft D, Scheiner O. Diagnosis of grass pollen allergy with recombinant timothy grass (Phleum pratense) pollen allergens. Int Arch Allergy Immunol 1992;97:287294.
  • 28
    Moser M, Crameri R, Brust E, Suter M, Menz G. Diagnostic value of recombinant Aspergillus fumigatus allergen I/a for skin testing and serology. J Allergy Clin Immunol 1994;93:111.
  • 29
    Valenta R, Lidholm J, Niederberger V, Hayek B, Kraft D, Grönlund H. The recombinant allergen-based concept of component-resolved diagnostics and immunotherapy (CRD and CRIT). Clin Exp Allergy 1999;29:896904.
  • 30
    Ebner C, Schenk S, Szépfalusi Z, Hoffmann K, Ferreira F, Willheim M et al. Multiple T cell specificities for Bet v I, the major birch pollen allergen, within single individuals. Studies using specific T cell clones and overlapping peptides. Eur J Immunol 1993;23:15231527.
  • 31
    van Neerven RJ, van de Pol MM, van Milligen FJ, Jansen HM, Aalberse RC, Kapsenberg ML. Characterization of cat dander-specific T lymphocytes from atopic patients. J Immunol 1994;152:42034210.
  • 32
    Valenta R, Sperr WR, Ferreira F, Valent P, Sillaber C, Tejkl M et al. Induction of specific histamine release from basophils with purified natural and recombinant birch pollen allergens. J Allergy Clin Immunol 1993;91:8897.
  • 33
    Sehon LZ, Mohapatra SS. Induction of IgE antibodies in mice with recombinant grass pollen antigens. Immunology 1992;76:158163.
  • 34
    Zhang L, Mohapatra SS. Antigen- and isotype-specific immune responses to a recombinant antigen-allergen chimeric (RAAC) protein. J Immunol 1993;151:791799.
  • 35
    Ferreira FD, Mayer P, Sperr WR, Valent P, Seiberler S, Ebner C et al. Induction of IgE antibodies with predefined specificity in rhesus monkeys with recombinant birch pollen allergens, Bet v 1 and Bet v 2. J Allergy Clin Immunol 1996;97:95103.
  • 36
    Vrtala S, Mayer P, Ferreira F, Susani M, Sehon AH, Kraft D et al. Induction of IgE antibodies in mice and rhesus monkeys with recombinant birch pollen allergens: different allergenicity of Bet v 1 and Bet v 2. J Allergy Clin Immunol 1996;98:913921.
  • 37
    Breiteneder H, Ferreira F, Hoffmann-Sommergruber K, Ebner C, Breitenbach M, Rumpold H et al. Four recombinant isoforms of Cor a I, the major allergen of hazel pollen, show different IgE-binding properties. Eur J Biochem 1993;212:355362.
  • 38
    Ball T, Vrtala S, Sperr WR, Valent P, Susani M, Kraft D et al. Isolation of an immunodominant IgE hapten from an epitope expression cDNA library. Dissection of the allergic effector reaction. J Biol Chem 1994;269:2832328328.
  • 39
    Ferreira F, Hirtenlehner K, Jilek A, Godnik-Cvar J, Breiteneder H, Grimm R et al. Dissection of immunoglobulin E and T lymphocyte reactivity of isoforms of the major birch pollen allergen Bet v 1: potential use of hypoallergenic isoforms for immunotherapy. J Exp Med 1996;183:599609.
  • 40
    Smith AM, Chapman MD. Reduction in IgE binding to allergen variants generated by site-directed mutagenesis: contribution of disulfide bonds to the antigenic structure of the major house dust mite allergen Der p 2. Mol Immunol 1996;33:399405.
  • 41
    Vrtala S, Hirtenlehner K, Vangelista L, Pastore A, Eichler HG, Sperr WR et al. Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments: candidates for a novel form of specific immunotherapy. J Clin Invest 1997;99:16731681.
  • 42
    Takai T, Yokota T, Yasue M, Nishiyama C, Yuuki T, Mori A et al. Engineering of the major house dust mite allergen Der f 2 for allergen-specific immunotherapy. Nat Biotechnol 1997;15:754758.
  • 43
    Zeiler T, Taivainen A, Rytkonen M, Rautiainen J, Karjalainen H, Mäntyjärvi R et al. Recombinant allergen fragments as candidate preparations for allergen immunotherapy. J Allergy Clin Immunol 1997;100:721727.
  • 44
    Valenta R. The future of antigen-specific immunotherapy of allergy. Nat Rev Immunol 2002;2:446453.
  • 45
    Larché M. Update on the current status of peptide immunotherapy. J Allergy Clin Immunol 2007;119:906909.
  • 46
    Kahlert H, Suck R, Weber B, Nandy A, Wald M, Keller W et al. Characterization of a hypoallergenic recombinant Bet v 1 variant as a candidate for allergen-specific immunotherapy. Int Arch Allergy Immunol 2008;145:193206.
  • 47
    Mothes-Luksch N, Stumvoll S, Linhart B, Focke M, Krauth MT, Hauswirth A et al. Disruption of allergenic activity of the major grass pollen allergen Phl p 2 by reassembly as a mosaic protein. J Immunol 2008;181:48644873.
  • 48
    Vrtala S, Hirtenlehner K, Susani M, Akdis M, Kussebi F, Akdis CA et al. Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen Bet v 1. FASEB J 2001;15:20452047.
  • 49
    Campana R, Vrtala S, Maderegger B, Dall’antonia Y, Zafred D, Blatt K et al. Altered IgE epitope presentation: a model for hypoallergenic activity revealed for Bet v 1 trimer. Mol Immunol 2011;48:431441.
  • 50
    Edlmayr J, Niespodziana K, Linhart B, Focke-Tejkl M, Westritschnig K, Scheiblhofer S et al. A combination vaccine for allergy and rhinovirus infections based on rhinovirus-derived surface protein VP1 and a nonallergenic peptide of the major timothy grass pollen allergen Phl p 1. J Immunol 2009;182:62986306.
  • 51
    Niespodziana K, Focke-Tejkl M, Linhart B, Civaj V, Blatt K, Valent P et al. A hypoallergenic cat vaccine based on Fel d 1-derived peptides fused to hepatitis B PreS. J Allergy Clin Immunol 2011. In press.
  • 52
    Focke M, Swoboda I, Marth K, Valenta R. Developments in allergen-specific immunotherapy: from allergen extracts to allergy vaccines bypassing allergen-specific immunoglobulin E and T cell reactivity. Clin Exp Allergy 2010;40:385397.
  • 53
    Niederberger V, Horak F, Vrtala S, Spitzauer S, Krauth MT, Valent P et al. Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc Natl Acad Sci USA 2004;101:1467714682.
  • 54
    Rak S. Clinical results with a hypoallergenic recombinant birch pollen allergen derivative. 2009. Presented at 27th Congr., EAACI 2009, Warsaw, June 6–10
  • 55
    Menz G, Dolecek C, Schonheit-Kenn U, Ferreira F, Moser M, Schneider T et al. Serological and skin-test diagnosis of birch pollen allergy with recombinant Bet v I, the major birch pollen allergen. Clin Exp Allergy 1996;26:5060.
  • 56
    Pauli G, Oster JP, Deviller P, Heiss S, Bessot JC, Susani M et al. Skin testing with recombinant allergens rBet v 1 and birch profilin, rBet v 2: diagnostic value for birch pollen and associated allergies. J Allergy Clin Immunol 1996;97:11001109.
  • 57
    Kulig M, Bergmann R, Klettke U, Wahn V, Tacke U, Wahn U. Natural course of sensitization to food and inhalant allergens during the first 6 years of life. J Allergy Clin Immunol 1999;103:11731179.
  • 58
    Laffer S, Spitzauer S, Susani M, Pairleitner H, Schweiger C, Grönlund H et al. Comparison of recombinant timothy grass pollen allergens with natural extract for diagnosis of grass pollen allergy in different populations. J Allergy Clin Immunol 1996;98:652658.
  • 59
    Movérare R, Westritschnig K, Svensson M, Hayek B, Bende M, Pauli G et al. Different IgE reactivity profiles in birch pollen-sensitive patients from six European populations revealed by recombinant allergens: an imprint of local sensitization. Int Arch Allergy Immunol 2002;128:325335.
  • 60
    Westritschnig K, Sibanda E, Thomas W, Auer H, Aspöck H, Pittner G et al. Analysis of the sensitization profile towards allergens in central Africa. Clin Exp Allergy 2003;33:2227.
  • 61
    Stumvoll S, Westritschnig K, Lidholm J, Spitzauer S, Colombo P, Duro G et al. Identification of cross-reactive and genuine Parietaria judaica pollen allergens. J Allergy Clin Immunol 2003;111:974979.
  • 62
    Kazemi-Shirazi L, Niederberger V, Linhart B, Lidholm J, Kraft D, Valenta R. Recombinant marker allergens: diagnostic gatekeepers for the treatment of allergy. Int Arch Allergy Immunol 2002;127:259268.
  • 63
    Birkner T, Rumpold H, Jarolim E, Ebner H, Breitenbach M, Skvaril F et al. Evaluation of immunotherapy-induced changes in specific IgE, IgG and IgG subclasses in birch pollen allergic patients by means of immunoblotting. Correlation with clinical response. Allergy 1990;45:418426.
  • 64
    Schmid-Grendelmeier P. Recombinant allergens. For routine use or still only science? Hautarzt 2010;61:946953.
  • 65
    Ball T, Sperr WR, Valent P, Lidholm J, Spitzauer S, Ebner C et al. Induction of antibody responses to new B cell epitopes indicates vaccination character of allergen immunotherapy. Eur J Immunol 1999;29:20262036.
  • 66
    Ball T, Fuchs T, Sperr WR, Valent P, Vangelista L, Kraft D et al. B cell epitopes of the major timothy grass pollen allergen, Phl p 1, revealed by gene fragmentation as candidates for immunotherapy. FASEB J 1999;13:12771290.
  • 67
    Movérare R, Elfman L, Vesterinen E, Metso T, Haahtela T. Development of new IgE specificities to allergenic components in birch pollen extract during specific immunotherapy studied with immunoblotting and Pharmacia CAP System. Allergy 2002;57:423430.
  • 68
    Mothes N, Heinzkill M, Drachenberg KJ, Sperr WR, Krauth MT, Majlesi Y et al. Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. Clin Exp Allergy 2003;33:11981208.
  • 69
    Hiller R, Laffer S, Harwanegg C, Huber M, Schmidt WM, Twardosz A et al. Microarrayed allergen molecules: diagnostic gatekeepers for allergy treatment. FASEB J 2002;16:414416.
  • 70
    Harwanegg C, Laffer S, Hiller R, Mueller MW, Kraft D, Spitzauer S et al. Microarrayed recombinant allergens for diagnosis of allergy. Clin Exp Allergy 2003;33:713.
  • 71
    Gadermaier G, Wopfner N, Wallner M, Egger M, Didierlaurent A, Regl G et al. Array-based profiling of ragweed and mugwort pollen allergens. Allergy 2008;63:15431549.
  • 72
    Constantin C, Quirce S, Poorafshar M, Touraev A, Niggemann B, Mari A et al. Micro-arrayed wheat seed and grass pollen allergens for component-resolved diagnosis. Allergy 2009;64:10301037.
  • 73
    Lin J, Bardina L, Shreffler WG, Andreae DA, Ge Y, Wang J et al. Development of a novel peptide microarray for large-scale epitope mapping of food allergens. J Allergy Clin Immunol 2009;124:315322.
  • 74
    Hochwallner H, Schulmeister U, Swoboda I, Balic N, Geller B, Nystrand M et al. Microarray and allergenic activity assessment of milk allergens. Clin Exp Allergy 2010;40:18091818.
  • 75
    van Hage-Hamsten M, Kronqvist M, Zetterström O, Johansson E, Niederberger V, Vrtala S et al. Skin test evaluation of genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1: results obtained with a mix of two recombinant Bet v 1 fragments and recombinant Bet v 1 trimer in a Swedish population before the birch pollen season. J Allergy Clin Immunol 1999;104:969977.
  • 76
    Pauli G, Purohit A, Oster JP, De Blay F, Vrtala S, Niederberger V et al. Comparison of genetically engineered hypoallergenic rBet v 1 derivatives with rBet v 1 wild-type by skin prick and intradermal testing: results obtained in a French population. Clin Exp Allergy 2000;30:10761084.
  • 77
    Gafvelin G, Thunberg S, Kronqvist M, Grönlund H, Grönneberg R, Troye-Blomberg M et al. Cytokine and antibody responses in birch-pollen-allergic patients treated with genetically modified derivatives of the major birch pollen allergen Bet v 1. Int Arch Allergy Immunol 2005;138:5966.
  • 78
    Reisinger J, Horak F, Pauli G, van Hage M, Cromwell O, König F et al. Allergen-specific nasal IgG antibodies induced by vaccination with genetically modified allergens are associated with reduced nasal allergen sensitivity. J Allergy Clin Immunol 2005;116:347354.
  • 79
    Pree I, Reisinger J, Focke M, Vrtala S, Pauli G, van Hage M et al. Analysis of epitope-specific immune responses induced by vaccination with structurally folded and unfolded recombinant Bet v 1 allergen derivatives in man. J Immunol 2007;179:53095316.
  • 80
    Pree I, Shamji MH, Kimber I, Valenta R, Durham SR, Niederberger V. Inhibition of CD23-dependent facilitated allergen binding to B cells following vaccination with genetically modified hypoallergenic Bet v 1 molecules. Clin Exp Allergy 2010;40:13461352.
  • 81
    Purohit A, Niederberger V, Kronqvist M, Horak F, Gronneberg R, Suck R et al. Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivatives. Clin Exp Allergy 2008;38:15141525.
  • 82
    van Neerven RJ, Knol EF, Ejrnaes A, Würtzen PA. IgE-mediated allergen presentation and blocking antibodies: regulation of T-cell activation in allergy. Int Arch Allergy Immunol 2006;141:119129.
  • 83
    Klimek L, Bachert C, Doemer C, Meyer H, Narkus A. Specific immunotherapy with recombinant birch pollen allergen rBet v 1-FV is clinically efficacious. Allergy Clin Immunol Int 2005;1:15.
  • 84
    Jutel M, Jaeger L, Suck R, Meyer H, Fiebig H, Cromwell O. Allergen-specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol 2005;116:608613.
  • 85
    Pauli G, Larsen TH, Rak S, Horak F, Pastorello E, Valenta R et al. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis. J Allergy Clin Immunol 2008;122:951960.
  • 86
    Winther L, Poulsen LK, Robin B, Mélac M, Malling H. Safety and Tolerability of Recombinant Bet v 1 (rBet v 1) tablets in sublingual immunotherapy (SLIT). J Allergy Clin Immunol 2009;123:S215.
  • 87
    Larenas-Linnemann D. Oralair Birch, a recombinant major birch pollen allergen tablet for sublingual immunotherapy of allergic rhinitis caused by birch pollen. Curr Opin Investig Drugs 2010;11:586596.
  • 88
    Linhart B, Valenta R. Molecular design of allergy vaccines. Curr Opin Immunol 2005;17:646655.
  • 89
    Chapman MD, Ferreira F, Villalba M, Cromwell O, Bryan D, Becker WM et al. The European Union CREATE project: a model for international standardization of allergy diagnostics and vaccines. J Allergy Clin Immunol 2008;122:882889.